[go: up one dir, main page]

PT3406633T - Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos - Google Patents

Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos

Info

Publication number
PT3406633T
PT3406633T PT181635814T PT18163581T PT3406633T PT 3406633 T PT3406633 T PT 3406633T PT 181635814 T PT181635814 T PT 181635814T PT 18163581 T PT18163581 T PT 18163581T PT 3406633 T PT3406633 T PT 3406633T
Authority
PT
Portugal
Prior art keywords
specific
antibodies
methods
activable
activable antibodies
Prior art date
Application number
PT181635814T
Other languages
English (en)
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51299065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3406633(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of PT3406633T publication Critical patent/PT3406633T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
PT181635814T 2013-07-25 2014-07-25 Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos PT3406633T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361858402P 2013-07-25 2013-07-25

Publications (1)

Publication Number Publication Date
PT3406633T true PT3406633T (pt) 2022-05-04

Family

ID=51299065

Family Applications (1)

Application Number Title Priority Date Filing Date
PT181635814T PT3406633T (pt) 2013-07-25 2014-07-25 Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos

Country Status (17)

Country Link
US (2) US11161906B2 (pt)
EP (3) EP3024851B1 (pt)
JP (4) JP6693872B2 (pt)
KR (1) KR102216088B1 (pt)
CN (2) CN105722859B (pt)
AU (2) AU2014292924B2 (pt)
BR (1) BR112016001611B1 (pt)
CA (1) CA2918795A1 (pt)
DK (2) DK3024851T3 (pt)
ES (2) ES2912932T3 (pt)
HR (1) HRP20220553T1 (pt)
IL (1) IL243752B (pt)
PL (1) PL3406633T3 (pt)
PT (1) PT3406633T (pt)
RS (1) RS63152B1 (pt)
RU (1) RU2727836C2 (pt)
WO (1) WO2015013671A1 (pt)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
AU2013251310B2 (en) 2012-04-27 2018-02-15 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
JP6598680B2 (ja) 2013-04-02 2019-10-30 中外製薬株式会社 Ｆｃ領域改変体
CA2913051C (en) 2013-05-28 2023-09-05 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
HRP20240939T1 (hr) 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
AU2015236288A1 (en) * 2014-03-26 2016-09-15 Siemens Healthcare Diagnostics Inc. Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof
SMT201900745T1 (it) * 2014-05-30 2020-01-14 Henlix Biotech Co Ltd Anticopri anti-recettore del fattore di crescita epidermico (egfr)
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
CA2956014C (en) * 2014-07-25 2023-10-31 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
HRP20201747T1 (hr) 2014-11-20 2020-12-25 F. Hoffmann - La Roche Ag Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
AU2015373910B2 (en) * 2015-01-02 2021-11-18 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
AU2016206707A1 (en) * 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
SG10201913297TA (en) * 2015-03-13 2020-02-27 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
EP3708585A1 (en) * 2015-05-04 2020-09-16 CytomX Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
IL310251A (en) * 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
US11400157B2 (en) 2015-05-13 2022-08-02 Chugai Seiyaku Kabushiki Kaisha Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
US9994638B2 (en) * 2015-05-20 2018-06-12 Immunwork Inc. Peptide core-based multi-arm linkers for treating infectious diseases
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN108137705B (zh) 2015-07-21 2022-11-08 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
WO2017019729A1 (en) * 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
EP3336184A4 (en) 2015-08-11 2019-01-23 Osaka University ANTIBODY
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EA039736B1 (ru) * 2015-09-15 2022-03-04 Сайтомкс Терапьютикс, Инк. Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения
PL3349595T3 (pl) 2015-09-18 2020-06-01 Société des Produits Nestlé S.A. Wytrawne koncentraty o płynnej teksturze na bazie dwóch skrobi
MX2018003820A (es) 2015-10-02 2018-12-10 F Hoffmann ­La Roche Ag Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
US12102689B2 (en) 2015-11-09 2024-10-01 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
DK3377103T4 (en) 2015-11-19 2025-05-19 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10533157B1 (en) 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN108713026B (zh) * 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 四价抗psgl-1抗体及其用途
EP3192810A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
ES2947230T3 (es) * 2016-03-22 2023-08-03 Hoffmann La Roche Moléculas biespecíficas para linfocitos T activadas por proteasa
SG11201808085WA (en) * 2016-03-22 2018-10-30 Hoffmann La Roche Protease-activated t cell bispecific molecules
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
RS67145B1 (sr) 2016-05-20 2025-09-30 Harpoon Therapeutics Inc Proteini sa jednolančanim varijabilnim fragmentom koji vezuju cd3
EP3474901B1 (en) 2016-06-27 2025-08-06 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
KR102102734B1 (ko) 2016-08-05 2020-04-22 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
IL265046B2 (en) * 2016-08-30 2025-04-01 Xencor Inc Bispecific immunomodulatory antibodies that bind to costimulatory and checkpoint receptors
CN106632681B (zh) 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CA3040343A1 (en) * 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CA3041340A1 (en) * 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CN109923128A (zh) 2016-11-15 2019-06-21 基因泰克公司 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
MX2019006624A (es) 2016-12-09 2019-08-01 Seattle Genetics Inc Anticuerpos bivalentes enmascarados por helices superenrolladas.
JP7141407B2 (ja) 2016-12-13 2022-09-22 エフ．ホフマン－ラ ロシュ アーゲー 腫瘍試料における標的抗原の存在を決定する方法
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
FI3582806T3 (fi) 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
MX2019010156A (es) * 2017-02-27 2020-01-09 Dragonfly Therapeutics Inc Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110382542B (zh) * 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
KR102367658B1 (ko) * 2017-03-29 2022-02-25 타이페이 메디컬 유니이버시티 항원 특이적 t 세포 및 그의 용도
JP7164544B2 (ja) 2017-04-11 2022-11-01 インヒブルクス インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
CN108690138A (zh) * 2017-04-12 2018-10-23 鸿运华宁（杭州）生物医药有限公司 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
CN110891974B (zh) 2017-05-12 2021-08-06 哈普恩治疗公司 间皮素结合蛋白质
AU2018265860B2 (en) 2017-05-12 2022-08-11 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
BR112019024632A2 (pt) * 2017-05-23 2020-06-16 Dragonfly Therapeutics, Inc. A proteína de ligação nkg2d, cd16 e um tumor-antigénio associado
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP3645050A4 (en) * 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
JP7474193B2 (ja) * 2017-06-25 2024-04-24 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
WO2019005641A1 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
JP7399852B2 (ja) * 2017-06-25 2023-12-18 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
EP3655779A1 (en) * 2017-07-20 2020-05-27 CytomX Therapeutics, Inc. Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
KR20200040819A (ko) 2017-08-16 2020-04-20 브리스톨-마이어스 스큅 컴퍼니 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제
KR20240170847A (ko) 2017-09-08 2024-12-04 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
CR20200196A (es) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Proteínas trispecìficas y mètodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SG11202002384VA (en) * 2017-10-14 2020-04-29 Cytomx Therapeutics Inc Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3723763A4 (en) * 2017-12-11 2021-10-20 Triphase Research And Development III Corp. ANTI-CD22-MAYTANSIN ANTIBODY CONJUGATES, RELATED COMBINATIONS AND METHODS OF USE
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
EP3749361A1 (en) 2018-02-08 2020-12-16 F. Hoffmann-La Roche AG Bispecific antigen-binding molecules and methods of use
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
WO2019183218A1 (en) 2018-03-20 2019-09-26 Cytomx Therapeutics, Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
CN112218686A (zh) 2018-04-11 2021-01-12 印希比股份有限公司 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
WO2019213444A1 (en) 2018-05-02 2019-11-07 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CA3099419A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
BR112020023118A2 (pt) 2018-05-14 2021-04-13 Werewolf Therapeutics, Inc. Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes
SG11202011330PA (en) 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
SG11202010890PA (en) * 2018-06-04 2020-11-27 Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
CA3103414A1 (en) 2018-06-14 2019-12-19 Bioatla, Inc. Multi-specific antibody constructs
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
BR112021001616A2 (pt) * 2018-07-31 2021-05-04 Amgen Inc. formulações farmacêuticas de anticorpos mascarados
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
MX2021003628A (es) * 2018-10-01 2021-05-27 Amgen Inc Metodos para reducir la agregacion de anticuerpos biespecificos.
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
BR112021009106A2 (pt) 2018-11-12 2021-08-10 Debiopharm International S.A. compostos antibióticos, métodos de fabricação dos mesmos, composições farmacêuticas que os contêm e seus usos
CN120484127A (zh) 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
WO2020232305A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
CN114245806A (zh) 2019-05-14 2022-03-25 哈普恩治疗公司 EpCAM结合蛋白及使用方法
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
WO2020250940A1 (ja) * 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
EP4382129A3 (en) 2019-06-17 2024-07-03 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
KR20210043475A (ko) 2019-10-10 2021-04-21 주식회사 와이바이오로직스 다중 특이적 융합 단백질 및 이의 용도
AU2020379735A1 (en) * 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
CN118459602A (zh) * 2019-11-06 2024-08-09 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CA3161783A1 (en) * 2019-12-06 2021-06-10 Oncoone Research & Development Gmbh Anti-oxmif/anti-cd3 bispecific antibody constructs
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
EP4097129A1 (en) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CN115643806A (zh) * 2020-01-31 2023-01-24 璟尚生物制药公司 双特异性t细胞接合器
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
IL296634A (en) 2020-04-09 2022-11-01 Cytomx Therapeutics Inc Preparations containing activatable antibodies
AR122018A1 (es) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y clec12a
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022032037A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il23 receptor synthetic cytokines and methods of use
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
US12297281B2 (en) 2020-08-05 2025-05-13 Synthekine, Inc. IL10RA binding molecules and methods of use
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
CN116829585A (zh) 2020-08-05 2023-09-29 辛德凯因股份有限公司 Il27受体结合相关的组合物和方法
MX2023001490A (es) 2020-08-05 2023-04-27 Synthekine Inc Moleculas de union a il27r\03b1 y metodos de uso.
CN117043188A (zh) 2020-08-05 2023-11-10 辛德凯因股份有限公司 Gp130结合分子及使用方法
WO2022032042A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12 receptor synthetic cytokines and methods of use
EP4192857A4 (en) 2020-08-05 2025-07-23 Synthekine Inc IL10RB-BINDING MOLECULES AND METHODS OF USE THEREOF
WO2022032023A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il23r binding molecules and methods of use
CN117242088A (zh) 2020-08-05 2023-12-15 辛德凯因股份有限公司 Il10受体结合分子和使用方法
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
US20240034806A1 (en) * 2020-12-09 2024-02-01 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
US20240165162A1 (en) * 2021-04-08 2024-05-23 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and combinations with bispecific antibodies
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
IL312143A (en) 2021-10-15 2024-06-01 Amgen Inc An activatable polypeptide complex
AU2022365116A1 (en) 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
WO2023150672A1 (en) * 2022-02-04 2023-08-10 Duke University Compositions for and methods of treating hematological cancers
KR20240161096A (ko) * 2022-02-11 2024-11-12 인테리우스 바이오테라퓨틱스, 인코포레이티드 융합성 라브도바이러스 당단백질 및 이의 용도
CN114316062B (zh) * 2022-03-02 2022-06-07 珠海臻谱基因科技有限公司北京分公司 靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
TWI874962B (zh) 2022-04-13 2025-03-01 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法
JP2025537782A (ja) * 2022-11-15 2025-11-20 エフ． ホフマン－ラ ロシュ アーゲー 活性化可能なエフェクタードメインを有する組換え結合タンパク質
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta
WO2025189116A1 (en) * 2024-03-08 2025-09-12 Synthetic Design Lab, Inc. Multivalent multispecific constructs for targeted payload delivery
US20250297006A1 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2025237931A1 (en) * 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2026024841A1 (en) * 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
WO1991001752A1 (en) 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
WO2005047461A2 (en) 2003-08-18 2005-05-26 The Regents Of The University Of California Polypeptide display libraries and methods of making and using thereof
PL1673398T3 (pl) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP3181575B1 (en) 2005-08-31 2021-03-17 The Regents of The University of California Cellular libraries of peptide sequences (clips) and methods of using the same
AR057807A1 (es) 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
WO2007105027A1 (en) * 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
GB0605702D0 (en) * 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2007147001A2 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
EP4059964A1 (en) 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Cross-species-specific binding domain
CN101675077B (zh) 2007-04-03 2013-09-04 安进研发（慕尼黑）股份有限公司 跨种特异性的双特异性结合剂
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP2190861A4 (en) * 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
JP6126782B2 (ja) 2008-10-01 2017-05-10 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
EP3375790A1 (en) * 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
US20110217302A1 (en) * 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
EP2356131A4 (en) * 2008-12-08 2012-09-12 Tegopharm Corp MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS
US8895702B2 (en) * 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
DK2396036T3 (en) 2009-02-13 2017-10-16 Immunomedics Inc Immune conjugates with an intracellular cleavable compound
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US20100241584A1 (en) * 2009-03-20 2010-09-23 Bank Of America Flexible design pension account
US9315584B2 (en) 2009-03-25 2016-04-19 Tohoku University LH-type bispecific antibody
MX2011011669A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las misma.
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2012025525A1 (en) * 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
CA2817964C (en) * 2010-11-17 2018-06-12 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
MY173899A (en) 2011-05-21 2020-02-26 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
JP5960138B2 (ja) * 2011-06-28 2016-08-02 第一三共株式会社 リン酸エステル誘導体
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AR087601A1 (es) 2011-08-23 2014-04-03 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US9718893B2 (en) 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
AU2013251310B2 (en) 2012-04-27 2018-02-15 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AU2013278075B2 (en) * 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
WO2013192546A1 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
KR20150036606A (ko) 2012-07-13 2015-04-07 자임워크스 인코포레이티드 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014052462A2 (en) * 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
EP2941643A4 (en) * 2013-01-04 2016-09-28 Cytomx Therapeutics Inc Compositions and methods for detecting proteinase activity in biological systems
EP2986559B1 (en) * 2013-04-19 2018-12-05 ExxonMobil Chemical Patents Inc. Molecular sieve cok-5 and its synthesis
EP3003387A1 (en) * 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions and methods for conjugating activatable antibodies
JP6546162B2 (ja) 2013-07-05 2019-07-17 ゲンマブ エー／エス ヒト化またはキメラｃｄ３抗体
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
AU2014293011A1 (en) * 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
US9540440B2 (en) * 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP3099319A2 (en) * 2014-01-31 2016-12-07 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
US10669337B2 (en) * 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
JP2018520092A (ja) * 2015-05-04 2018-07-26 サイトメックス セラピューティクス インコーポレイテッド 抗ＩＴＧａ３抗体、活性化可能抗ＩＴＧａ３抗体、およびその使用方法
IL310251A (en) * 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
EP3708585A1 (en) * 2015-05-04 2020-09-16 CytomX Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
SG11202002384VA (en) 2017-10-14 2020-04-29 Cytomx Therapeutics Inc Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019213444A1 (en) 2018-05-02 2019-11-07 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

Also Published As

Publication number Publication date
BR112016001611B1 (pt) 2024-01-09
RU2016106115A (ru) 2017-08-30
JP7036860B2 (ja) 2022-03-15
JP2016525551A (ja) 2016-08-25
CN105722859A (zh) 2016-06-29
RS63152B1 (sr) 2022-05-31
ES2912932T3 (es) 2022-05-30
JP2024083331A (ja) 2024-06-20
CN113150164A (zh) 2021-07-23
EP3024851A1 (en) 2016-06-01
DK3406633T3 (da) 2022-03-28
JP2020114872A (ja) 2020-07-30
CN105722859B (zh) 2021-05-07
AU2020200981A1 (en) 2020-02-27
EP3406633B1 (en) 2022-03-02
DK3024851T3 (en) 2018-08-06
HRP20220553T1 (hr) 2022-06-10
NZ755670A (en) 2022-03-25
CA2918795A1 (en) 2015-01-29
ES2683268T3 (es) 2018-09-25
RU2020123264A (ru) 2020-10-14
IL243752B (en) 2021-10-31
US20210238291A1 (en) 2021-08-05
AU2014292924A1 (en) 2016-02-11
RU2727836C2 (ru) 2020-07-24
JP6693872B2 (ja) 2020-05-13
RU2016106115A3 (pt) 2018-07-24
WO2015013671A1 (en) 2015-01-29
US11161906B2 (en) 2021-11-02
EP3406633A1 (en) 2018-11-28
PL3406633T3 (pl) 2022-05-23
NZ716064A (en) 2022-03-25
BR112016001611A2 (pt) 2017-08-29
EP3024851B1 (en) 2018-05-09
AU2020200981B2 (en) 2021-11-18
US20150079088A1 (en) 2015-03-19
JP2022065174A (ja) 2022-04-26
IL243752A0 (en) 2016-04-21
EP4067383A1 (en) 2022-10-05
KR20160035065A (ko) 2016-03-30
AU2014292924B2 (en) 2019-11-21
KR102216088B1 (ko) 2021-02-15

Similar Documents

Publication Publication Date Title
IL290972A (en) Anti-vista antibodies and fragments
PT3406633T (pt) Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
IL304772A (en) Antibodies, uses and methods
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
DK3336106T3 (da) Anti-fcrh5-antistoffer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
DK2951203T3 (da) Heterodimere proteiner
CL2015002750A1 (es) Anticuerpos humanos pac1
DK3041857T3 (da) Protein a-kromatografi
DK3068800T3 (da) FcRn-specifikke antistoffer
EP2980212A4 (en) HEATABLE CELLOBIOHYDROLASE
BR112015021083A2 (pt) método
HRP20190085T1 (hr) Anti-cd52 protutijela
DK3065774T3 (da) Anti-CCL17-antistoffer
BR112016000450A2 (pt) oscilador, e método
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도
BR112015029076A2 (pt) método
HUE047455T2 (hu) HPA-1A elleni antitestek
DK3047028T5 (da) Fermenteringsfremgangsmåde
DK3089990T3 (da) Forbedret proteinekspression
DK3089991T3 (da) Forbedret proteinekspression
FI20135408L (fi) Autentikointimenetelmä